Omega Healthcare Investors (OHI) Q4 2024 earnings summary

Executive summary

• Fourth quarter 2024 saw continued revenue and EBITDA growth, supporting FAD of $0.70 per share and leverage reduction below 4.0x debt to EBITDA.

• Net income for Q4 2024 was $116 million ($0.41/share), up from $57 million ($0.22/share) in Q4 2023; full year net income reached $418 million ($1.55/share).

• 2024 featured disciplined capital deployment with 36 transactions totaling $1.1 billion, including $340 million in Q4 investments; the 2025 acquisition pipeline remains active.

• Management changes included naming a new President and CIO, with confidence in leadership continuity.

• Issued $438 million in equity in Q4 and $1.2 billion for the year, repaid $400 million in senior unsecured notes, and extended credit facility maturities.

Financial highlights

• Q4 2024 revenue was $279.3 million, up from $239 million in Q4 2023, driven by new investments and operator restructurings.

• Nareit FFO for Q4 was $196 million ($0.68/share), AFFO $214 million ($0.74/share), and FAD $202 million ($0.70/share), all up year-over-year.

• Q4 expenses decreased by $36.2 million year-over-year, mainly due to lower credit loss provisions and reduced acquisition costs.

• Full year 2024 revenues totaled $1.1 billion, up $101.7 million from 2023; full year expenses fell by $144.7 million, primarily from lower impairments and credit loss recoveries.

• Q4 FAD slightly exceeded Q3, despite 14 million new shares issued late Q3 not fully included in Q3 share count.

Outlook and guidance

• 2025 AFFO guidance is $2.90–$2.98 per share, reflecting Q1 dilution from Q4 share issuances, offset by escalators and new opportunities.

• Guidance assumes no change in revenue from operators on accrual basis, continued improvement in Maplewood rent, $56 million in asset sales, and no material market interest rate changes.

• Quarterly G&A expense projected at $12–$14 million in 2025, with cash positioned to repay a $600 million bond maturing January 2026.